Laying Out Analysis of Raludotatug Deruxtecan Dose Optimisation in Patients with Platinum-Resistant Ovarian Cancer
- Overviewing R-DXd design and mechanism of action
- Presenting clinical activity of R-DXd in patients with platinum-resistant ovarian cancer (PROC) from Phase I and Phase II/III REJOICE-Ov01 study
- Exploring the outcome of dose optimisation analysis of R-DXd in patients with PROC